Drug Profile
Research programme: cancer therapies - Akebia Therapeutics
Alternative Names: KRX 0404Latest Information Update: 21 Dec 2018
Price :
$50
*
At a glance
- Originator Keryx Biopharmaceuticals
- Class
- Mechanism of Action Apoptosis stimulants; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Dec 2018 Akebia Therapeutics merged with Keryx Pharmaceuticals to form Akebia Therapeutics
- 27 Jul 2009 No development reported - Preclinical for Cancer in USA (IV)
- 01 May 2007 Preclinical trials in Cancer in USA (IV)